THE EINDs and the Open Label Extension were opened up and require the same criteria as CD12. That is what he is posting about. After the FDA has received the CD12 data they have not shut it down.
The reasoning here is that if the data from CD12 was bad, the EINDs and the Open Label Extension related to CD12 would be shut down, but they have not been shut down.
This looks like there will be a smooth usage transition from EIND and OLE to EUA.
Show me some data that shows where Leronlimab treated patients got worse after they were treated.
Market Data 
Markets 
AI
